Impact of antiretroviral therapy on renal function among HIV-infected tanzanian adults: A retrospective cohort study

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Mpondo, Bonaventura C T ^a,b   Kalluvya, Samuel E ^a,b   Peck, Robert N ^a,b,c   Kabangila, Rodrick ^a,b   Kidenya, Benson R ^a   Ephraim, Lucheri ^a,b   Fitzgerald, Daniel W ^c   Downs, Jennifer A ^a,b,c  

^a CATHOLIC UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b Bugando Medical Centre   (Tanzania)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CREATININE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; OUTCOME ASSESSMENT; OUTPATIENT; PREVALENCE; PROTEINURIA; RETROSPECTIVE STUDY; TANZANIA; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; KIDNEY FUNCTION TEST; MORTALITY; PATHOGENICITY; PROGNOSIS; RENAL INSUFFICIENCY; RISK FACTOR; SURVIVAL RATE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HIV; HIV INFECTIONS; HUMANS; KIDNEY FUNCTION TESTS; MALE; PREVALENCE; PROGNOSIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TANZANIA;

EID: 84896282196     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089573     Document Type: Article

References (29)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860. doi:10.1056/NEJM199803263381301. (Pubitemid 28135961)
2. Selik RM, Byers RH, Dworkin MS (2002) Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 29: 378-387. (Pubitemid 34288892)
3. Han TM, Naicker S, Ramdial PK, Assounga AG (2006) A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 69: 2243-2250. doi:10.1038/sj.ki.5000339. (Pubitemid 43882112)
4. Sarfo FS, Keegan R, Appiah L, Shakoor S, Phillips R, et al. (2013) High prevalence of renal dysfunction and association with risk of death amongst HIV-infected Ghanaians. J Infect 67: 43-50. doi:10.1016/j.jinf.2013.03.008.
5. Emem CP, Arogundade F, Sanusi A, Adelusola K, Wokoma F, et al. (2008) Renal disease in HIV-seropositive patients in Nigeria: an assessment of prevalence, clinical features and risk factors. Nephrol Dial Transpl 23: 741-746. doi:10.1093/ndt/gfm836. (Pubitemid 351767653)
6. Mulenga LB, Kruse G, Lakhi S, Cantrell RA, Reid SE, et al. (2008) Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS 22: 1821-1827. doi:10.1097/QAD.0b013e328307a051.
7. Msango L, Downs JA, Kalluvya SE, Kidenya BR, Kabangila R, et al. (2011) Renal dysfunction among HIV-infected patients starting antiretroviral therapy. AIDS 25: 1421-1425. doi:10.1097/QAD.0b013e328348a4b1.
8. Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, et al. (2012) Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients. Am J Kidney Dis 60: 539-547. doi:10.1053/j.ajkd.2012.03. 006.
9. Peters PJ, Moore DM, Mermin J, Brooks JT, Downing R, et al. (2008) Antiretroviral therapy improves renal function among HIV-infected Ugandans. Kidney Int 74: 925-929. doi:10.1038/ki.2008.305.
10. Reid A, Stöhr W, Walker AS, Williams IG, Kityo C, et al. (2008) Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 46: 1271-1281. doi:10.1086/533468. (Pubitemid 351589914)
11. Scheurer D (2004) Rapid reversal of renal failure after initiation of HAART: a case report. AIDS Read 14: 443-447.
12. Kirchner JT (2002) Resolution of renal failure after initiation of HAART: 3 cases and a discussion of the literature. AIDS Read 12: 103-105, 110-112.
13. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, et al. (2004) Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 18: 541-546. (Pubitemid 38365883)
14. Estrella M, Fine DM, Gallant JE, Rahman MH, Nagajothi N, et al. (2006) HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients. Clin Infect Dis 43: 377-380. doi:10.1086/505497. (Pubitemid 44078912)
15. Cosgrove CJ, Abu-Alfa AK, Perazella MA (2002) Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy. Am J Med Sci 323: 102-106. (Pubitemid 34651563)
16. Atta MG, Gallant JE, Rahman MH, Nagajothi N, Racusen LC, et al. (2006) Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transpl 21: 2809-2813. doi:10.1093/ndt/gfl337. (Pubitemid 44542235)
17. Szczech LA, Edwards LJ, Sanders LL, van der Horst C, Bartlett JA, et al. (2002) Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 57: 336-341. (Pubitemid 34477470)
18. Laradi A, Mallet A, Beaufils H, Allouache M, Martinez F (1998) HIV-associated nephropathy: outcome and prognosis factors. Groupe d'Etudes Néphrologiques d'Ile de France. J Am Soc Nephrol 9: 2327-2335.
19. Szczech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, et al. (2002) Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 61: 195-202. doi:10.1046/j.1523-1755.2002.00094.x. (Pubitemid 34075147)
20. Choi AI, Shlipak MG, Hunt PW, Martin JN, Deeks SG (2009) HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS 23: 2143-2149. doi:10.1097/QAD.0b013e3283313c91.
21. Post FA, Campbell LJ, Hamzah L, Collins L, Jones R, et al. (2008) Predictors of renal outcome in HIV-associated nephropathy. Clin Infect Dis 46: 1282-1289. doi:10.1086/529385. (Pubitemid 351589915)
22. Tanzania Commission for AIDS (TACAIDS), Zanzibar AIDS Commission (ZAC), National Bureau of Statistics (NBS), Office of the Chief Government Statistician (OCGS), Macro Inc. International (2008) Tanzania HIV/AIDS and Malaria Indicator Survey 2007-08. Dar es Salaam, Tanzania.
23. Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med 317: 1098.
24. Wools-Kaloustian K, Gupta SK, Muloma E, Owino-Ong'or W, Sidle J, et al. (2007) Renal disease in an antiretroviral-naïve HIV-infected outpatient population in Western Kenya. Nephrol Dial Transpl 22: 2208-2212. doi:10.1093/ndt/gfm223. (Pubitemid 47248464)
25. World Health Organization (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Available: http://www.who.int/hiv/pub/guidelines/arv2013/en/index.html. Accessed 2013 Jul 22.
26. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, et al. (2010) Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51: 496-505. doi:10.1086/655681.
27. Chi BH, Mwango A, Giganti MJ, Sikazwe I, Moyo C, et al. (2011) Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia. J Acquir Immune Defic Syndr 58: 475-481. doi:10.1097/QAI.0b013e31823058a3.
28. Bygrave H, Kranzer K, Hilderbrand K, Jouquet G, Goemaere E, et al. (2011) Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural Lesotho. PLoS One 6: e17609. doi:10.1371/journal. pone.0017609.
29. De Beaudrap P, Diallo MB, Landman R, Guèye NF, Ndiaye I, et al. (2010) Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215). AIDS Res Hum Retrovir 26: 1221-1227. doi:10.1089/aid.2009.0261.